MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell carcinoma (RCC) patients. PD-1 ...

Monday on the RealClearPolitics radio show, Tom Bevan, Andrew Walworth, and White House reporter Phil Wegmann discuss Vice ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Here's the latest information on three Texas Department of Transportation projects and a project from a local developer in the New Caney and Porter areas.

A transgender employee of the National Security Agency is suing the Trump administration and trying to block enforcement of a presidential executive order and other policies the employee says violate ...

US judge tosses Trump challenge to New York immigration-related law A federal judge on Tuesday dismissed a lawsuit the U.S. Department of Justice filed challenging a New York law that President Donald ...

The emergence of super wood, transparent wood, mouldable wood and wood–geopolymer hybrids is redefining the structural and functional performance of bioinspired engineered wood products. Meanwhile, ...

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC, papillary ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. David Kindness is a Certified Public ...

New Orleans, LA, August 7, 2023-Patrick and Shannon Able completed the purchase and assumed ownership of RCC Flooring, a commercial flooring company based in New Orleans, Louisiana on July 31, 2023.

A week before The Game Awards 2025, Megabonk appeared to be stepping out of the competition altogether. It’s developer had voluntarily withdrawn the title from one of the major indie categories, ...

Arcus Biosciences Inc. and partner Gilead Sciences Inc. are scrapping phase III work with anti-TIGIT antibody domvanalimab after an independent data monitoring committee said the drug will fail in ...